

Abstract

 Drug repurposing may provide a solution to the substantial challenges facing *de novo* drug development. Given that 66% of FDA-approved drugs in 2021 were supported by human genetic evidence, drug repurposing methods based on genome wide association studies (GWAS), such as drug gene-set analysis, may prove an efficient way to identify new treatments. However, to our knowledge, drug gene-set analysis has not been tested in non-psychiatric phenotypes, and previous implementations may have contained statistical biases when testing groups of drugs. Here, 1201 drugs were tested for association with hypercholesterolemia, type 2 diabetes, coronary artery disease, asthma, schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease. We show that drug gene-set analysis can identify clinically relevant drugs 33 (e.g., simvastatin for hypercholesterolemia $[p = 2.82E-06]$; mitiglinide for type 2 diabetes $[p = 1.82E-06]$ 2.66E-07]) and drug groups (e.g., C10A for coronary artery disease [*p =* 2.31E-05]; insulin secretagogues for type 2 diabetes [*p* = 1.09E-11]) for non-psychiatric phenotypes. Additionally, we demonstrate that when the overlap of genes between drug-gene sets is considered we find no groups containing approved drugs for the psychiatric phenotypes tested. However, several drug groups were identified for psychiatric phenotypes that may contain possible repurposing candidates, such as ATC codes J02A (*p* = 2.99E-09) and N07B (*p* = 0.0001) for schizophrenia. Our results demonstrate that clinically relevant drugs and groups of drugs can be identified using drug gene-set analysis for a number of phenotypes. These findings have implications for quickly identifying novel treatments based on the genetic mechanisms underlying diseases.

Keywords: genome-wide association study, drug repurposing, gene-set analysis.

46 Over the last 15 years, the use and effectiveness of genome-wide association studies (GWAS) have 47 developed rapidly, resulting in the discovery of over 270,000 phenotypically associated genetic 48 variants^{1,2}. While translating GWAS findings into use for pharmacological and clinical purposes has 49 been challenging, seminal work by Nelson et al. and King et al. demonstrated that drugs with 50 genetic support for efficacy were 2-5 times more likely to gain approval status compared to 51 compounds with no such evidence^{3,4}. In fact, 66% of FDA-approved drugs in 2021 are supported 52 by human genetic evidence that link the compounds to their gene product targets⁵. GWAS results 53 have been used as early as 2009 to prioritize novel targets for pharmaceuticals⁶. For example, 54 Wang et al identified the IL12/IL23 pathway as a novel target for Crohn's disease, which supported 55 the subsequent development of Ustekinumab, an antibody that binds with IL12 and IL23 6.7 .

 However, the development of novel pharmaceuticals is a time and financially intensive 57 process, averaging 12.8 years and \$2.6 billion dollars for a single new medication^{8,9}. Despite wide advances across science and technology in the past 60 years, the cost for approved drugs per billion 59 spent has seen an 80-fold increase after adjusting for inflation¹⁰. Additionally, the development of novel drugs for psychiatric and neurological conditions has been particularly affected, with several large pharmaceutical companies shutting down research and development for psychiatric disorders 62 . ϵ entirely¹¹. Given the size of the challenges facing *de novo* drug development, interest has turned towards drug repurposing, the process of identifying new clinical indications (the phenotype a drug is approved to treat) for currently approved medications¹². Moreover, the vast quantities of GWAS results provide excellent data regarding possible gene targets to be leveraged for drug repurposing. To date, many methods have been created to repurpose drugs using GWAS summary statistics, including candidate gene approaches, Mendelian randomization, pharmagenic 68 enrichment scores, transcriptomic signature matching, and drug gene-set analysis $13-17$.

 Drug gene-set analysis, an approach first published by De Jong and Breen¹⁸, can be used to identify candidate drugs based on GWAS results. Gene-set, or pathway, analysis involves mapping genetic variants (e.g., single nucleotide polymorphisms [SNPs], copy number variants [CNVs]) to genes, and grouping genes into sets based on, for example, *a priori* biological functions or co-73 expression networks, and testing each gene set for association with the phenotype^{19,20}. For drug gene-set analysis, gene sets are created for drugs based on known biological and/or chemical properties. For example, a drug-gene set can be made of the genes that code the proteins targeted by a specific drug, and this gene set can be tested for association with a phenotype. While De Jong & Breen found no gene-sets to be significantly associated with schizophrenia, their nominally significant results included the known schizophrenia drug trifluoperazine, and metoclopramide and neratinib, which target dopamine receptors and tyrosine kinases (both implicated in 80 schizophrenia)¹⁸. This method has been continued by Gaspar and colleagues, who developed the 81 drug repurposing tool Drug Targetor, which is largely based on drug gene-set analysis $17,21$.

 However, while drug gene-set analysis has been tested in schizophrenia and bipolar disorder, it has never been verified in non-psychiatric phenotypes and, to our knowledge, no drugs have ever been found to be significantly associated with schizophrenia. Additionally, previous research testing groups of drugs for associations have used methods that violated statistical 86 assumptions of independence¹⁷. Here, we apply drug gene-set analysis to eight phenotypes – hypercholesterolemia (i.e., high cholesterol), type 2 diabetes, coronary artery disease, asthma, schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease – and use a novel statistical approach to test if groups of drugs are enriched for genetic signal associated with a phenotype while accounting for the covariance between drugs. Our objectives were first, to assess the ability of drug gene-set analysis at prioritizing clinically relevant drugs for each phenotype, and second, to identify candidate drugs for repurposing for the phenotypes investigated.

Results

 We extracted data for drug-gene targets and interactions from the Clue Repurposing Hub and the Drug Gene Interaction Database and created a gene set for each drug (*n* = 1201) composed of the genes whose protein products are known to be targeted by or interact with the drug in question 97 (Figure 1A)^{22,23}. To test drug-gene set associations, competitive gene-set analysis was performed 98 using the MAGMA software tool for each of the eight phenotypes¹⁹ while conditioning on a gene set of all drug target genes in our data (*n* = 2281; Methods). This was done to ensure that significant drug-gene set associations were due to effects unique to drug pathways, and not due to common properties shared by all drug target genes (e.g., many gene products targeted by drugs are receptors). For the individual drug-gene sets see Supplementary Table S1.

Individual drug-gene set results

 We identified 22 significant drug-trait associations across the eight phenotypes we investigated using drug gene-set analysis (Table 1 & 2; Fig 1A). Drugs were significantly associated with each of the phenotypes except for asthma and Parkinson's disease. For the non-psychiatric/neurological phenotypes, many of our results included drugs approved to treat the diseases in question. For instance, all 4 of the drugs associated with type 2 diabetes – glipizide, glyburide, mitiglinide, and 110 repaglinide – are approved for type 2 diabetes^{24–26} (Tables 1 & 2). Similarly, statin drugs (e.g., pravastatin and atorvastatin) were associated with both coronary artery disease and hypercholesterolemia, which are used to lower LDL cholesterol and prevent myocardial 113 infarctions²⁷. Likewise, lomitapide and fenofibrate, which were also associated with coronary artery disease, are drugs used to treat hypercholesterolemia, a known risk factor for coronary 115 artery disease^{28–30}. We found no significant associations between approved psychiatric drugs and the psychiatric phenotypes that were tested. However, the antiepileptic drug gabapentin was

- 117 significantly associated with schizophrenia, which is known to have some efficacy in treating
- 118 . psychiatric disorders³¹. For all individual drug gene-set analysis results see Supplementary Tables
- 119 S2 S9.
- 120

121 **Table 1. Summary of results**

 Total tested = total number of drug-gene sets tested for each phenotype; Total approved = number of 123 approved drug-gene sets tested for each phenotype; % approved = % of total drugs tested that are approved for each phenotype; N signif. drugs = total number of significant drugs for each phenotype (see Table 2 for all significant drugs). Bonferroni-corrected p-value thresholds for hypercholesterolemia = 0.05 / 1162 = 4.3E-05, for type 2 diabetes = 0.05 / 1056 = 4.73E-05, and for coronary artery disease, asthma,

127 schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease = 0.05 / 1172 = 4.27E-05; N 128 signif. and approved = number of significant drugs that are approved for the given phenotype; % signif. of

129 approved drugs = % of the total number of approved drugs for a tested phenotype that were significant.

131

132 **Figure 1 Overview of drug gene-set analysis**. **(A)** Gene sets were created for every drug (*n* = 1201) consisting of 133 the genes whose protein products are targeted by or interact with that drug. Since similar drugs share gene targets it
134 is possible for overlap of genes to occur between drugs. MAGMA was used for gene-set analysis t 134 is possible for overlap of genes to occur between drugs. MAGMA was used for gene-set analysis to test for significant
135 relationships between drug-gene sets and each phenotype. Drug-gene sets were tested using a cond 135 relationships between drug-gene sets and each phenotype. Drug-gene sets were tested using a conditional competitive 136 gene-set analysis (Methods). (B) Drug groups were tested for enrichment of genetic signal using 136 gene-set analysis (Methods). **(B)** Drug groups were tested for enrichment of genetic signal using a modified multiple 137 linear regression model. This was done for ATC III groups ($n = 85$), mechanism of action drug 137 linear regression model. This was done for ATC III groups ($n = 85$), mechanism of action drug groups ($n = 79$), and clinical indication drug groups ($n = 118$) with $n > 5$ (Methods). (C) Lastly, gene sets were created 138 clinical indication drug groups (*n* = 118) with *n* > 5 (Methods). (C) Lastly, gene sets were created for each subcategory
139 of each grouping method (i.e., ATC III codes, clinical indications, and mechanisms of acti 139 of each grouping method (i.e., ATC III codes, clinical indications, and mechanisms of action) and tested for association
140 using the same MAGMA protocol as drugs in panel A (Methods). using the same MAGMA protocol as drugs in panel A (Methods). 141

Drug gene set	Phenotype	Approved	N genes	MAGMA p
atorvastatin	TCL	No	60	1.77E-11
lomitapide	TCL	Yes	$\overline{4}$	7.33E-08
pravastatin	TCL	Yes	34	6.15E-11
saroglitazar	TCL	No	$\overline{2}$	3.22E-05
simvastatin	TCL	Yes	52	2.82E-06
mitiglinide	T ₂ D	Yes	$\overline{4}$	2.66E-07
glyburide	T ₂ D	Yes	19	2.29E-05
repaglinide	T ₂ D	Yes	15	$9.01E-16$
glipizide	T ₂ D	Yes	6	1.08E-05
aminocaproic acid	CAD	No	3	1.59E-11
atorvastatin	CAD	No	61	8.40E-08
fenofibrate	CAD	No	28	7.63E-06
lomitapide	CAD	No	$\overline{4}$	3.96E-11
lovastatin	CAD	Yes	43	3.38E-06
pravastatin	CAD	No	35	1.59E-07
amlodipine	SCZ	No	12	1.51E-05
benidipine	SCZ	No	$\overline{2}$	1.32E-05
felodipine	SCZ	No	13	1.53E-05
gabapentin	SCZ	No	38	3.80E-08
manidipine	BIP	No	$\overline{2}$	2.64E-06
nilvadipine	BIP	No	$\overline{2}$	2.64E-06
lubiprostone	ALZ	No	$\overline{2}$	3.76E-06

142 **Table 2. Individual drug-gene set results for all phenotypes**

143 Drug-gene set = drugs whose gene set was significant after Bonferroni correction for the number of drug 144 gene sets tested (see Table 1 for number of drugs tested for each phenotype); Phenotype = the phenotype 145 the drug was associated with. TCL = hypercholesterolemia, T2D = type 2 diabetes, CAD = coronary artery 146 disease, BIP = bipolar disorder, SCZ = schizophrenia, ALZ = Alzheimer's disease; Approved = whether the 147 drug is approved to be used for the phenotype it was associated with; N genes = number of genes in the 148 drug gene set; MAGMA $p = p$ -value for individual drug gene-sets from a competitive gene-set analysis while 149 conditioning on a gene set of all drug target genes in the data; No drugs were significantly associated with 150 Asthma or Parkinson's disease.

Drug group enrichment

 Drug gene sets were grouped in three ways: by Anatomical Therapeutic Classification (ATC) III code, by clinical indication, and by the mechanism of action. Previous research that tested for enrichment of genetic signal within groups of drug gene sets used drug enrichment curves derived 156 from a Wilcoxon Mann Whitney U test¹⁷. However, due to the overlap of genes between drug gene sets, the assumption of data independence needed for a Wilcoxon Mann Whitney U test is not valid. Thus, here we instead employed a multiple linear regression approach, modeling the drug group membership as a predictor of the MAGMA drug gene-set t-statistic, to test whether drugs in that drug group exhibited (on average) more strongly associated drug gene sets than other drugs. Overlap between gene sets is accounted for through the residual covariance matrix of the regression model.

163 Each drug group with 5 or more drugs within the ATC ($n = 85$), mechanism of action ($n =$ 164 79), and clinical indication ($n = 118$) categories was tested for enrichment of genetic signal using the method above. Bonferroni correction was applied by correcting for the number of drug groups tested within each of the three grouping methods, and then using a family-wise correction for the number of grouping methods used. Therefore, the Bonferroni-corrected p-value threshold was (0.05/85) / 3 = 0.00019 for ATC drug groups, (0.05/79) / 3 = 0.00021 for mechanism of action 169 drug groups, and $(0.05/118) / 3 = 0.00014$ for clinical indication drug groups. For all drug groups see Supplementary Tables S10 – S12, and for the drug group enrichment results see Supplemental Table S13 – S22.

 As seen in Figure 2 (top), we identified 14 drug groups that were significantly enriched for genetic signal across the 8 phenotypes we examined. For the non-psychiatric/neurological phenotypes, we found at least one drug group containing one or more drugs approved for the phenotype tested. For hypercholesterolemia, we identified two drug groups where more than 50%

 of the drugs were approved for hypercholesterolemia (C10A and HMGCR inhibitors), and we identified the mechanism of action group insulin secretagogues for type 2 diabetes, which contains only drugs approved for type 2 diabetes. None of the drug groups that were associated with our psychiatric and neurological phenotypes contained approved drugs. However, the ATC code N07B – drugs used for addictive disorders – that is associated with schizophrenia contains several drugs (e.g., naltrexone, buprenorphine) that have shown significant improvements in treating both 182 positive and negative symptoms in the disorder³². As seen in the bottom panels of Figure 2, none of the clinical indication drug groups for the phenotypes we examined were significantly associated with our phenotype after correction for multiple tests. The clinical indication groups for Parkinson's disease, type 2 diabetes, and hypercholesterolemia were nominally enriched for genetic signal for 186 each of their respective phenotypes.

188

189 **Figure 2 Drug group enrichment.** Drug groups were tested for enrichment of genetic signal with each 190 phenotype. The left panels show the -log₁₀ p-values for each drug group, and the right panels show the 191 percentage of approved drugs in the group. The top panels show all drug groups that are significant after 192 multiple testing correction. The bottom panels portray the drug groups containing all approved drugs for 193 each of the 8 phenotypes that were tested. TCL = hypercholesterolemia; T2D = type 2 diabetes; CAD = 194 coronary artery disease; AST = asthma, SCZ = schizophrenia; BIP = bipolar disorder; PKD = Parkinson's

195 disease; ALZ = Alzheimer's disease. See Supplementary Tables S13 – S14 for full results.

 To examine the genes driving the significant results seen in the top panel of Figure 2, we generated heatmaps of the drug-gene sets for the most significant drug groups for each phenotype; insulin secretagogues for type 2 diabetes (Fig 3A), the clinical indication drug group of urticaria for asthma (Fig 3B), ATC code J02A for schizophrenia (Fig 3C), and ATC code A04A for Alzheimer's disease (Fig 3D). For the C10A heatmaps associated with hypercholesterolemia and 201 coronary artery disease see Supplemental Figures S1 and S2.

202 As seen in Figure 3A, the genes with the highest MAGMA $-log_{10}$ p-values targeted by insulin 203 secretagogues are *KCNQ1*, *TCF7L2*, *PPAR*g, *IGF2BP2*, and *KCNJ11*. All these genes are known to be 204 associated with type 2 diabetes and affect biological processes like insulin secretion and fat storage 205 in adipose tissue^{33,34}. For the clinical indication drug group urticaria (Fig 3B), there are several 206 genes with evidence linking them to asthma. Namely, research has indicated that the *PPAR*^{δ} gene 207 targeted by desloratadine may be a promising therapeutic target for asthma, with desloratadine 208 itself – an allergy medication – having shown efficacy in treating seasonal allergic asthma^{35,36}. 209 Moreover, another study found that *EHMT2* was differentially expressed in patients with asthma 210 compared to healthy controls³⁷. The targets of drugs in the ATC J02A group also contain genes 211 related to schizophrenia. Antigen levels for *DPYD* were found to be elevated in individuals with 212 schizophrenia compared with healthy controls, and it is known to be associated with schizophrenia 213 via previous genome-wide association studies^{38,39}. Moreover, there is evidence indicating that 214 splicing variation of *CYP2D6* may play a role in schizophrenia as well⁴⁰. Lastly, the ATC group 215 A04A associated with Alzheimer's disease targets a number of serotonergic receptors, which have 216 shown promise as therapeutic targets in animal models by reducing levels of amyloid-beta⁴¹. 217 Interestingly, all of the drug groups depicted appear to be driven by a variety of genes, as opposed 218 to a small number of genes targeted by all drugs in a group (with the exceptions of *PPAR_Y*, *KCNJ11*, 219 and *ABCC8* for the insulin secretagogues).

220

221

222 223 **Figure 3 Heatmaps of drug group enrichment results.** The heatmaps depict the drug-gene sets from 224 drug groups that were significantly associated with a phenotype, with color signifying the gene's -log₁₀ p-
225 value from MAGMA. Panel (A) depicts drug-gene sets from the insulin secretagogues group associated 225 value from MAGMA. Panel **(A)** depicts drug-gene sets from the insulin secretagogues group associated 226 with type 2 diabetes, panel **(B)** illustrates the drug-gene sets from the clinical indication group urticaria 227 associated with asthma, panel **(C)** shows the drug-gene sets from ATC code J02A associated with 228 schizophrenia, and panel **(D)** portrays the drug-gene sets from ATC code A04A associated with Alzheimer's 229 disease. Drug gene set names are listed on the *y*-axis, and gene names are listed on the *x*-axis. Color = -
230 log₁₀ p-value from gene association tests in MAGMA. log_{10} p-value from gene association tests in MAGMA.

 Next, we compared the gene targets of approved drugs for each phenotype to further investigate why drug-gene set analysis was better at identifying approved drugs for the non- psychiatric/neurological phenotypes that were tested. As seen in Figure 4, there are 38 gene targets of approved drugs (8.44% of drug target genes) that are significant after Bonferroni correction for the non-psychiatric/neurological phenotypes investigated, compared to 17 significant gene targets (3.21% of drug target genes) for drugs approved for the psychiatric and neurological phenotypes. Moreover, each of the four non-psychiatric/neurological phenotypes has at least 4 significant genes targeted by approved drugs, while bipolar disorder and Parkinson's disease have only 1 significant gene targeted by an approved drug, and Alzheimer's disease has none. This may explain why none of the significant drug groups associated with the psychiatric and neurological phenotypes contained any drugs approved specifically for those disease and disorders.

245 **Figure 4 Manhattan plots of gene targets for approved drugs.** The top panel depicts the gene-level 246 Manhattan plot for the targets of approved drugs for the four non-psychiatric/neurological phenotypes (*n* = 247 450), and the bottom panel depicts the same for the psychiatric/neurological phenotypes (*n* = 530). Genes 248 that are labeled are significant after Bonferroni correction for their respective phenotype (since the number 249 of genes tested varied per phenotype, different Bonferroni thresholds were applied to each phenotype; see 250 Methods). Color = phenotype; shape = even and odd chromosomes; TCL = hypercholesterolemia; $T2D$ = 251 type 2 diabetes; CAD = coronary artery disease; AST = asthma, SCZ = schizophrenia; BIP = bipolar 252 disorder; PKD = Parkinson's disease; ALZ = Alzheimer's disease. 253

-
- 254

Merged drug gene-set analysis

 Some drug-gene sets have a very small number of gene targets, resulting in lower power 258 to detect associations with phenotypes²⁰. Additionally, many drug categories in our data do not contain enough drugs to test for enrichment. Therefore, to be able to include drug targets with small gene set sizes and to test association for drug categories with low numbers of drugs, we also created gene sets by grouping drugs again by ATC III code, clinical indication, and mechanism of action. For each category within the grouping methods, a single gene set was created made up of all the gene targets for drugs in the group (Figure 1C), resulting in 164 ATC III code gene sets, 515 clinical indication gene sets, and 354 mechanism of action gene sets (Tables S23 – S25). Competitive gene-set analysis was performed with the same protocol used when testing individual drug-gene sets for each of the three types of grouped drug-gene sets (Methods). We identified 32 significant categorical gene set-trait relationships, with every phenotype but asthma and Parkinson's disease having at least one associated gene set. For all significant categorical drug gene sets see Supplementary Table S26, and for all categorical drug-gene set results see Supplementary Tables S27 – S50.

Drug similarity networks

 For each phenotype, we created network graphs to investigate how the top drugs per 274 phenotype cluster based on their Jaccard similarity coefficient⁴² (Figure 5), which is calculated using the proportion of gene targets shared by both drugs (see Methods). Central nodes in each network graph were defined using all drugs with a MAGMA competitive gene-set analysis p-value < 0.01 per phenotype. All drugs with a Jaccard similarity of 0.25 or greater with a central node were included as peripheral nodes. Figure 5A displays the similarity network graph for drugs

 associated with hypercholesterolemia and Figure 5B illustrates the similarity of drugs associated with schizophrenia.

 As may be expected, statin drugs approved for hypercholesterolemia tend to cluster together, while the other two significant drugs, lomitapride and probucol, have no similar compounds (Figure 5A). There is also a cluster of PPAR agonists around the significant drug 284 saroglitazar and nominally significant drug bezafibrate, which both target the PPAR α/γ subunits. Figure 5B demonstrates that almost none of the Bonferroni-significant drugs identified using drug gene-set analysis for schizophrenia cluster with approved schizophrenia drugs, with the exception being one approved drug sharing an edge with benidipine. Most nominally significant drugs for schizophrenia (Figure 5B) appear in the same large cluster, which ranges from antiepileptics in one subcluster (e.g., ethosuximide), calcium channel blockers in the middle (e.g., felodipine), and ACE inhibitors on the other side (e.g., quinapril). The exception is gabapentin, which appears by itself connected to only one other drug, spironolactone. Interestingly, spironolactone has been found to improve schizophrenia symptoms in mice by acting as an antagonist to the NRG1-ERBB4 293 signaling pathway, and is currently being tested in humans as an add-on treatment for SCZ^{43} . The rest of the approved schizophrenia drugs (triangles) appear in the cluster centered around amisulpride, azaperone, domperidone, and perospirone. For network graphs of all phenotypes see 296 the Supplemental materials (Figures $S3 - S7$).

 Figure 5 Drug similarity networks. Drug similarity was calculated using the Jaccard index to measure the proportion of shared gene targets between every pair of drugs. Drugs nominally associated with our 301 phenotypes ($p < 0.01$) were used as central nodes, with peripheral nodes being any drug with a Jaccard similarity > 0.25 with any central node. Panel **(A)** displays the results for hypercholesterolemia, and **(B)** shows the network for drugs associated with schizophrenia. Triangle = approved drug for the phenotype, square = Bonferroni-significant drug that is not approved for the phenotype, edge width = Jaccard similarity coefficient.

Discussion

 In the current study, we applied drug gene-set analysis to four non-psychiatric/neurological phenotypes and four psychiatric/neurological phenotypes, to investigate the performance of drug gene-set analysis at identifying clinically relevant drugs (i.e., drugs approved to treat the phenotypes we examined), and to identify potential repurposing candidates. We found the first drugs whose targets were significantly enriched for genes associated with hypercholesterolemia, type 2 diabetes, coronary artery disease, schizophrenia, and Alzheimer's disease using this method, and identified drugs with the same mechanism of action (calcium channel blockers) as those 314 published in the latest genome-wide association study of bipolar disorder⁴⁴. In all, 22 drug-trait associations were identified across the eight phenotypes we examined. Notably, 4 of the 4 drugs identified for type 2 diabetes are approved to treat type 2 diabetes, and 3 statin drugs were significantly associated with both coronary artery disease and hypercholesterolemia, respectively^{24–} ^{26,45,46}. We also demonstrated that drug gene-set analysis does not have to be used to isolate single drugs for repurposing and can also pinpoint categories of drugs by using two different methods: by testing for the enrichment of individual drugs in a category and by combining gene targets of all drugs in a category into a single gene set, thereby also pointing into the direction of putative novel drug development that fall within an identified category. Specifically, we identified drug groups enriched for genetic signal for hypercholesterolemia, type 2 diabetes, coronary artery disease, and asthma that contained approved drugs for those diseases. Additionally, we found that the clinical indication drug groups for hypercholesterolemia, type 2 diabetes, and Parkinson's disease were nominally enriched.

 Phenotypes that were not enriched for drugs that are already approved for treatment may not reflect a shortcoming of drug gene-set analysis, but more so the gap between the gene products targeted by current treatments and the genes that are most associated with it as measured by

 genome-wide association studies. Thus, while no approved drugs for the psychiatric/neurological phenotypes examined here were identified, this may be because current treatments for these 332 diseases only target disease symptoms and not the underlying disease mechanisms^{$47-50$}. The results presented here establish that drug gene-set analysis can identify clinically relevant drugs – with accuracy varying across the phenotypes we examined – and is able to offer new drug candidates for repurposing.

 Across our drug gene-set analysis results there is evidence for repurposable drugs for several phenotypes. For instance, we find repeated evidence for the potential treatment of schizophrenia with calcium channel blockers. The calcium channel blockers felodipine, amlodipine, and benidipine were significantly associated with schizophrenia after Bonferroni correction. The use of calcium channel blockers in psychiatry has shown mixed efficacy in the literature. Previous research has tested the use of calcium channel blockers for psychiatric disorders and found them ineffective, although many of these studies used first-generation drugs (e.g., verapamil)⁵¹. Recent research has found that calcium channel blocker use is associated with reduced illness severity for schizophrenia and lower rates of psychiatric admission and self-harm during psychosis^{52,53}. Additionally, Lintunen et al. found that calcium channel blocker use was associated with lower risk for psychiatric hospitalization in individuals with schizophrenia, an effect which was specific to the calcium channel blocker subclass of dihydropyridines⁵⁴. This is a significant distinction, as drugs in this subclass are also known to have higher selectivity and permeability across the blood brain barrier, perhaps making them better candidates for psychiatric 350 use than first generation calcium channel blockers⁵¹. Notably, all calcium channel blockers that were identified for both schizophrenia and bipolar disorder, felodipine, amlodipine, benidipine, 352 manidipine, and nilvadipine, are all dihydropyridines⁵⁵. Likewise, one of the two drugs identified using drug gene-set analysis in the 2021 genome-wide association study on bipolar disorder was

354 nisoldipine, which is also a dihydropyridine calcium channel blocker⁴⁴. Thus, further research into the use of dihydropyridines in psychiatry may be warranted.

 Despite the promising results found here, drug gene-set analysis still leaves several questions unanswered regarding repurposable drugs prioritized with this method. First, drug gene- set analysis does not specifically test for direct associations between a drug and a phenotype. Rather, it tests whether the gene targets of drugs are enriched for genetic signal that is associated with a phenotype. Second, and perhaps most importantly, is that drug gene-set analysis does not indicate the direction of effect, meaning that drugs identified could either alleviate or exacerbate disease progression and symptoms. Additionally, drug gene-set analysis provides no information on the way a drug interacts with its targets (e.g., agonism versus antagonism). These two limitations mean that drug gene-set analysis may best be used in the first steps of a drug repurposing pipeline, or as one of several methods used to triangulate novel drugs for a phenotype⁵⁶. Drugs prioritized with drug gene-set analysis could be followed up using genomics approaches that consider gene expression (e.g., transcriptomic signature matching) or more 368 statistical approaches like Mendelian randomization¹⁵ or local genetic correlation analysis⁵⁷, using protein levels of the drug-gene targets for each gene in a drug gene set. This may prove tedious for drugs with large gene sets and may fail to capture interaction effects between different proteins. However, transcriptomic signature matching (e.g., correlating gene expression induced by a drug with the gene expression associated with a phenotype) could be an efficient follow-up for large drug-gene sets. Whilst the limitations above are important to note, they do not outweigh the benefits. Given the excessive financial and time challenges facing psychiatric drug development, a cheap in-silico, and quick method for genetically informed drug repurposing, such as drug gene- set analysis, may prove invaluable. The drug gene-set analysis pipeline used here is publicly available (Methods) and can be used with any user provided GWAS summary statistics.

Materials & Methods

 Data. *Clue Repurposing Hub*. The Clue Repurposing Hub is a publicly accessible, annotated data set of FDA-approved, clinical trial, and pre-clinical drugs. We extracted gene targets for every FDA- approved drug from the Clue Repurposing Hub that had a known clinical indication, disease 383 category, and mechanism of action $(n = 1201)$.

 Drug Gene Interaction Database. To augment the sets of gene targets downloaded from the Clue Repurposing Hub, we queried the Drug Gene Interaction Database API for additional genes targeted by or interacting with each compound in our data set. This database is publicly accessible.

 GWAS. Summary statistics for hypercholesterolemia, coronary artery disease, and Parkinson's 390 disease were downloaded from GWAS Atlas⁵⁸⁻⁶⁰ (https://atlas.ctglab.nl/). Summary statistics for type 2 diabetes were downloaded from the DIAGRAM Consortium website (http://diagram-392 consortium.org/downloads.html)³³, summary statistics for asthma were retrieved from GWAS 393 Catalog (https://www.ebi.ac.uk/gwas/ $)^{61}$, and those for bipolar disorder and schizophrenia were 394 accessed from the Psychiatric Genomics Consortium website^{44,61,62} (https://www.med.unc.edu/pgc/download-results/). Lastly, GWAS summary statistics for 396 Alzheimer's disease (excluding 23andme data) were downloaded from the CTG Lab website⁶³ (https://ctg.cncr.nl/software/summary_statistics).

 Analyses. *Drug gene-set analysis.* Drug gene-sets were created using the gene targets and interactions retrieved from both the Clue Repurposing Hub and Drug Gene Interaction Database 401 for every compound, resulting in 1201 drug gene sets with $n \ge 2$. Additionally, we created 3 types of drug gene-set by grouping drugs by clinical indication (*n* = 515), by mechanism of action

403 (*n* = 354), and by ATC III code (*n* = 164). Competitive gene-set analysis was performed separately 404 with MAGMA v1.09b for each type of drug-gene set, using the 1K Genomes European reference 405 panel^{19,64}. Competitive gene set analysis was computed while conditioning on a gene set of every 406 gene target in our data set $(n = 2281)$ to assess whether drug gene-set associations were specific 407 to the drug-gene set or driven by common properties of drug target genes.

408

 Drug group associations. Groups of drugs were examined for enrichment of genetic signal using a multiple linear regression model to estimate the effect of drug group membership on MAGMA t- statistics. Given that the MAGMA t-statistic is a measure of the degree to which a drug gene set is enriched for genetic signal for a phenotype, this allows us to test whether drugs in that drug group exhibited (on average) greater enrichment than other drugs.

414 Denoting the vector of drug gene-set t-statistics as Y and encoding a binary indicator 415 variable G_i for drug group *i*, scored 1 for drugs in that drug group and 0 otherwise, we fit the 416 model $Y = \beta_0 + C\beta_c + G_i\beta_c + \varepsilon = X\beta + \varepsilon$. Here, C is a covariate matrix containing the drug gene-417 set size as well as the log of the drug gene-set size, and ε is the residual term with distribution ~ MVN(0, % 418), where is the sampling correlation matrix of the MAGMA t-statistics. Combining 419 the intercept and predictor variables in X , the model can be estimated using Generalized Least 420 Squares, yielding the estimate $\hat{\beta} = (X^T S^{-1} X)^{-1} X^T S^{-1} Y$, with sampling covariance matrix $W =$ 421 $\hat{\sigma}^2(X^T S^{-1} X)^{-1}$. For the residual variance we have the estimate $\hat{\sigma}^2 = \frac{\hat{\epsilon}^T S^{-1} \hat{\epsilon}}{N-K}$, with $\hat{\epsilon} = Y - X\hat{\beta}$ and 422 with N the number of drugs and $K = 4$ the number of parameters in the regression equation.

423 For each drug group *j*, we test the null hypothesis $H_0: \beta_G = 0$ against the one-sided 424 alternative H_A : $\beta_G > 0$ using the test statistic $T = \frac{\widehat{\beta}_G}{\sqrt{W_G}}$, where W_G is the diagonal element of W 425 corresponding to $\hat{\beta}_G$ and T has a t-distribution with $N - K$ degrees of freedom. Correction for

426 multiple tests was done using a two-stage Bonferroni correction, correcting for the three grouping 427 methods used and then for the number of groups tested within each grouping method. This 428 resulted in a threshold of 0.05/ $N_g/3$ for each grouping method g with N_g the number of groups 429 for g, where $N_g = 85$ for the ATC III code drug groups, $N_g = 79$ for the mechanism of action drug 430 groups, and $N_g = 118$ for the clinical indication drug groups.

431

432 *Manhattan Plots of Genes Targeted by Approved Drugs.* The Bonferroni-significant thresholds for the 433 gene-level Manhattan plots were derived by $0.05/N_{x,y}$, where N_x is the number of genes tested in 434 MAGMA for a phenotype *y.* The Bonferroni-significant thresholds are as follows: 435 $p_{hypercholeterolemia} = 0.05/17493 = 2.86E-06, p_{diabetes} = 0.05/11631 = 4.29E-06, p_{cad} =$ 436 0.05/18180 = 2.75E-06, $p_{asthma} = 0.05/18315 = 2.73E-06$, $p_{schizophrenia} = 0.05/18265$ = 437 2.74E-06, $p_{bipolar} = 0.05/18262 = 2.74E-06$, $p_{parkinsons} = 0.05/18367 = 2.72E-06$, $p_{alzhemers} =$ 438 0.05/18409 = 2.72E-06.

439

 Drug Similarity Network Graphs. Network graphs were created to investigate how the top results cluster based on the similarity of their gene targets. The similarity of each pair of drugs was 442 evaluated using the Jaccard similarity coefficient, which is calculated using the formula $J(A, B)$ = $\frac{|A \cap B|}{|A \cup B|}$ for drug gene sets A and B, where $|A \cap B|$ denotes the number of genes shared by those 444 gene sets and $|A \cup B|$ the number of genes that occurs in at least one of the two gene sets. Central nodes for each phenotype were defined as drug-gene sets with a MAGMA gene-set analysis p-value \leq 0.01, and all drugs with a Jaccard index \geq 0.25 with a central node were included as peripheral nodes. Network graphs were created in Python using the package *networkx 2.6.3*.

Code availability

The software pipeline used to compute drug gene-set analysis and the drug group analyses is

458 publicly available and can be accessed here: https://github.com/nybell/drugsets.

Acknowledgments

 This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964874. DP is supported by the Netherlands Organization for Scientific Research - Gravitation project 'BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology' (024.004.012), and DP and EU are funded by the European Research Council advanced grant 'From GWAS to Function' (ERC-2018-ADG 834057). NYB, EU, EvW, and DP have no conflicts of interest to declare. CdL was funded by F. Hoffman-La Roche AG.

- 12. Lau, A. & So, H.-C. Turning genome-wide association study findings into opportunities for
- drug repositioning. *Computational and Structural Biotechnology Journal* **18**, 1639–1650 (2020).
- 13. Liu, J. Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel
- disease and highlight shared genetic risk across populations. *Nat Genet* **47**, 979–986 (2015).
- 14. Schmidt, A. F. *et al.* Genetic drug target validation using Mendelian randomisation. *Nat*
- *Commun* **11**, 3255 (2020).
- 15. Reay, W. R. & Cairns, M. J. Advancing the use of genome-wide association studies for drug repurposing. *Nat Rev Genet* (2021) doi:10.1038/s41576-021-00387-z.
- 16. So, H.-C. *et al.* Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry. *Nat Neurosci* **20**, 1342–1349 (2017).
- 17. Gaspar, H. A. & Breen, G. Drug enrichment and discovery from schizophrenia genome-wide
- association results: an analysis and visualisation approach. *Sci Rep* **7**, 12460 (2017).
- 18. de Jong, S., Vidler, L. R., Mokrab, Y., Collier, D. A. & Breen, G. Gene-set analysis based on
- the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.
- *J Psychopharmacol* **30**, 826–830 (2016).
- 19. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLoS Comput Biol* **11**, e1004219 (2015).
- 20. de Leeuw, C. A., Neale, B. M., Heskes, T. & Posthuma, D. The statistical properties of gene-set analysis. *Nat Rev Genet* **17**, 353–364 (2016).
- 21. Gaspar, H. A., Hübel, C. & Breen, G. Drug Targetor: a web interface to investigate the
- human druggome for over 500 phenotypes. *Bioinformatics* **35**, 2515–2517 (2019).

- 22. Corsello, S. M. *et al.* The Drug Repurposing Hub: a next-generation drug library and
- information resource. *Nat Med* **23**, 405–408 (2017).
- 23. Freshour, S. L. *et al.* Integration of the Drug–Gene Interaction Database (DGIdb 4.0) with
- open crowdsource efforts. *Nucleic Acids Research* **49**, D1144–D1151 (2021).
- 24. Plosker, G. L. & Figgitt, D. P. Repaglinide: A Pharmacoeconomic Review of its Use in Type
- 2 Diabetes Mellitus. *PharmacoEconomics* **22**, 389–411 (2004).
- 25. Phillippe, H. M. & Wargo, K. A. Mitiglinide for type 2 diabetes treatment. *Expert Opinion on Pharmacotherapy* **14**, 2133–2144 (2013).
- 26. Dahlén, A. D. *et al.* Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New
- Drugs in Clinical Trials and Global Sales. *Front. Pharmacol.* **12**, 807548 (2022).
- 27. Maron, D. J., Fazio, S. & Linton, M. F. Current Perspectives on Statins. *Circulation* **101**, 207–213 (2000).
- 28. Alonso, R., Cuevas, A. & Mata, P. Lomitapide: a review of its clinical use, efficacy, and tolerability. *Core Evid* **14**, 19–30 (2019).
- 29. Keating, G. M. & Croom, K. F. Fenofibrate: A Review of its Use in Primary Dyslipidaemia,
- the Metabolic Syndrome and Type 2 Diabetes Mellitus. *Drugs* **67**, 121–153 (2007).
- 30. Libby, P. & Theroux, P. Pathophysiology of Coronary Artery Disease. *Circulation* **111**,
- 3481–3488 (2005).
- 31. Ahmed, S. *et al.* Use of Gabapentin in the Treatment of Substance Use and Psychiatric
- Disorders: A Systematic Review. *Frontiers in Psychiatry* **10**, (2019).
- 32. Clark, S. D., Van Snellenberg, J. X., Lawson, J. M. & Abi-Dargham, A. Opioid antagonists
- are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of
- controlled trials. *Neuropsychopharmacol.* **45**, 1860–1869 (2020).

- diverse populations for discovery and translation. *Nat Genet* **54**, 560–572 (2022).
- 34. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using high-
- density imputation and islet-specific epigenome maps. *Nat Genet* **50**, 1505–1513 (2018).
- 35. Banno, A., Reddy, A. T., Lakshmi, S. P. & Reddy, R. C. PPARs: Key Regulators of Airway
- Inflammation and Potential Therapeutic Targets in Asthma. *Nucl Receptor Res* **5**, 101306
- (2018).
- 36. Berger, W. E., Schenkel, E. J., Mansfield, L. E., & Desloratadine Study Group. Safety and
- efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal
- congestion. *Ann Allergy Asthma Immunol* **89**, 485–491 (2002).
- 37. Stefanowicz, D. *et al.* Epigenetic modifying enzyme expression in asthmatic airway epithelial cells and fibroblasts. *BMC Pulm Med* **17**, 24 (2017).
- 38. Whelan, R., St Clair, D., Mustard, C. J., Hallford, P. & Wei, J. Study of Novel
- Autoantibodies in Schizophrenia. *Schizophrenia Bulletin* **44**, 1341–1349 (2018).
- 39. Ripke, S. *et al.* Biological insights from 108 schizophrenia-associated genetic loci. *Nature*
- **511**, 421–427 (2014).
- 40. Ma, L., Shcherbina, A. & Chetty, S. Variations and expression features of CYP2D6
- contribute to schizophrenia risk. *Mol Psychiatry* **26**, 2605–2615 (2021).
- 41. Claeysen, S., Bockaert, J. & Giannoni, P. Serotonin: A New Hope in Alzheimer's Disease? *ACS Chem. Neurosci.* **6**, 940–943 (2015).
- 42. Jaccard, P. The Distribution of the Flora in the Alpine Zone.1. *New Phytologist* **11**, 37–50 (1912).

- 43. Hasan, A. *et al.* Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling
- pathway for the treatment of schizophrenia: Study design and methodology of a multicenter
- randomized, placebo-controlled trial. *Contemp Clin Trials Commun* **17**, 100537 (2020).
- 44. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases
- provides new insights into the underlying biology. *Nat Genet* **53**, 817–829 (2021).
- 45. Agrawal, R. The first approved agent in the Glitazar's Class: Saroglitazar. *Curr Drug*
- *Targets* **15**, 151–155 (2014).
- 46. Aravind Sosale, S., Saboo, B. & Sosale, B. Saroglitazar for the treatment of
- hypertriglyceridemia in patients with type 2 diabetes: current evidence. *DMSO* 189 (2015)
- doi:10.2147/DMSO.S49592.
- 47. Rizek, P., Kumar, N. & Jog, M. S. An update on the diagnosis and treatment of Parkinson disease. *CMAJ* **188**, 1157–1165 (2016).
- 48. Cummings, J. New approaches to symptomatic treatments for Alzheimer's disease.
- *Molecular Neurodegeneration* **16**, 2 (2021).
- 49. Stępnicki, P., Kondej, M. & Kaczor, A. A. Current Concepts and Treatments of
- Schizophrenia. *Molecules* **23**, 2087 (2018).
- 50. McIntyre, R. S. *et al.* Bipolar disorders. *The Lancet* **396**, 1841–1856 (2020).
- 51. Harrison, P. J., Tunbridge, E. M., Dolphin, A. C. & Hall, J. Voltage-gated calcium channel
- blockers for psychiatric disorders: genomic reappraisal. *Br J Psychiatry* **216**, 250–253
- (2020).
- 52. Hayes, J. F. *et al.* Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase
- Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric

- Hospitalization and Self-Harm in Individuals With Serious Mental Illness. *JAMA Psychiatry* **76**, 382 (2019).
- 53. Van Dyke, P. & Thomas, K. L. Concomitant calcium channel blocker and antipsychotic
- therapy in patients with schizophrenia: Efficacy analysis of the CATIE-Sz phase 1 data. *Ann*
- *Clin Psychiatry* **30**, 6–16 (2018).
- 54. Lintunen, J., Lähteenvuo, M., Tiihonen, J., Tanskanen, A. & Taipale, H. Adenosine
- modulators and calcium channel blockers as add-on treatment for schizophrenia. *npj*
- *Schizophr* **7**, 1–7 (2021).
- 55. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018.
- *Nucleic Acids Research* **46**, D1074–D1082 (2018).
- 56. Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. *International Journal of Epidemiology* **45**, 1866–1886 (2016).
- 57. Werme, J., Sluis, S. van der, Posthuma, D. & Leeuw, C. A. de. *LAVA: An integrated*
- *framework for local genetic correlation analysis*. 2020.12.31.424652
- https://www.biorxiv.org/content/10.1101/2020.12.31.424652v2 (2021)
- doi:10.1101/2020.12.31.424652.
- 58. Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nat Genet* **45**, 1274–1283 (2013).
-
- 59. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for
- Parkinson's disease: a meta-analysis of genome-wide association studies. *The Lancet*
- *Neurology* **18**, 1091–1102 (2019).
- 60. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex
- traits. *Nat Genet* **51**, 1339–1348 (2019).

- 61. Han, Y. *et al.* Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma. *Nat Commun* **11**, 1776 (2020).
- 62. Consortium, T. S. W. G. of the P. G., Ripke, S., Walters, J. T. & O'Donovan, M. C. *Mapping*
- *genomic loci prioritises genes and implicates synaptic biology in schizophrenia*.
- 2020.09.12.20192922 https://www.medrxiv.org/content/10.1101/2020.09.12.20192922v1
- (2020) doi:10.1101/2020.09.12.20192922.
- 63. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals
- identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).
- 64. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).